Analysts Set Insulet Co. (NASDAQ:PODD) PT at $253.27

Shares of Insulet Co. (NASDAQ:PODD) have earned an average recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $253.27.

A number of equities analysts have weighed in on the company. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Citigroup raised their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Raymond James boosted their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Finally, Barclays increased their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th.

Insulet Stock Performance

Shares of PODD opened at $266.92 on Friday. Insulet has a 12 month low of $160.19 and a 12 month high of $279.40. The business’s fifty day simple moving average is $243.21 and its two-hundred day simple moving average is $212.74. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market cap of $18.72 billion, a price-to-earnings ratio of 45.71, a P/E/G ratio of 4.08 and a beta of 1.22.

Hedge Funds Weigh In On Insulet

Hedge funds have recently made changes to their positions in the business. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Insulet during the second quarter valued at about $32,000. Venturi Wealth Management LLC grew its position in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares in the last quarter. Finally, CVA Family Office LLC boosted its stake in Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.